Management of pituitary tumors

Annals of Internal Medicine

Volumn 129, Issue 6, 1998, Pages 472-483

  Shimon, Ilan ^a,b   Melmed, Shlomo ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANGIOPEPTIN; BROMOCRIPTINE; CABERGOLINE; CORTICOTROPIN; DOPAMINE RECEPTOR STIMULATING AGENT; ETOMIDATE; GONADORELIN ANTAGONIST; GROWTH HORMONE; HYDROCORTISONE; HYPOPHYSIS HORMONE; KETOCONAZOLE; LISURIDE; METYRAPONE; MITOTANE; OCTREOTIDE; PERGOLIDE MESILATE; PROLACTIN; QUINAGOLIDE; SOMATOSTATIN DERIVATIVE; THYROTROPIN;

ACROMEGALY; CANCER RADIOTHERAPY; HORMONE RELEASE; HUMAN; HYPOPHYSIS ADENOMA; PRIORITY JOURNAL; PROLACTINOMA; REVIEW; TRANSSPHENOIDAL SURGERY;

EID: 0032531231     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-129-6-199809150-00009     Document Type: Review

References (100)

1. Molitch ME. Prolactinoma. In: Melmed 5, ed. The Pituitary. Cambridge, MA: Blackwell Science; 1995:443-77.
2. Schlechte J, Dolan K, Sherman B, Chapler F, Luciano A. The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab. 1989;68:412-8.
3. Besser GM, Parke L, Edwards CR, Forsyth IA, McNeilly AS. Galactorrhoea: successful treatment with reduction of plasma prolactin levels by brom-ergocryptine. Br Med J. 1972;3:669-72.
4. Thorner MO, McNeilly AS, Hagan C, Besser GM. Long-term treatment of galactorrhea and hypogonadism with bromocriptine. Br Med J. 1974;2: 419-22.
5. Molitch ME, Thorner MO, Wilson C. Management of prolactinomas. J Clin Endocrinol Metab. 1997;82:996-1000.
6. Feigenbaum SL, Downey DE, Wilson CB, Jaffe RB. Transsphenoidal pituitary resection for preoperative diagnosis of prolactin-secreting pituitary adenoma in women: long term follow-up. J Clin Endocrinol Metab. 1996; 81:1711-9.
7. Vance ML, Evans WS, Thorner MO. Drugs five years later. Bromocriptine. Ann Intern Med. 1984;100:78-91.
8. Wood DF, Johnston JM, Johnston DG. Dopamine, the dopamine D2 receptor and pituitary tumours. Clin Endocrinol (Oxf). 1991;34:455-66.
9. Gomez F, Reyes FI, Faiman C. Nonpuerperal galactorrhea and hyperprolactinemia. Clinical findings, endocrine features and therapeutic responses in 56 cases. Am J Med. 1977;62:648-60.
10. Molitch ME, Elton RL, Blackwell RE, Caldwell B, Chang RJ, Jaffe R, et al. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab. 1985;60:698-705.
11. Liuzzi A, Dallabonzana D, Oppizzi G, Verde GG, Cozzi R, Chiodini P, et al. Low doses of dopamine agonists in the long-term treatment of macroprolactinomas. N Engl J Med. 1985;313:656-9.
12. Berezin M, Shimon I, Hadani M. Prolactinoma in 53 men: clinical characteristics and modes of treatment (male prolactinoma). J Endocrinol Invest. 1995;18:436-41.
13. Thorner MO, Martin WH, Rogol AD, Morris JL, Perryman RL, Conway BP, et al. Rapid regression of pituitary prolactinomas during bromocriptine treatment. J Clin Endocrinol Metab. 1980;51:438-45.
14. Bevan JS, Webster J, Burke CW, Scanlon MF. Dopamine agonists and pituitary tumor shrinkage. Endocr Rev. 1992;13:220-40.
15. Van't Verlaat JW, Croughs RJ. Withdrawal of bromocriptine after long-term therapy for macroprolactinomas: effect on plasma prolactin and tumour size. Clin Endocrinol. 1991;34:175-8.
16. Johnston DG, Hall K, Kendall-Taylor P, Patrick D, Watson M, Cook DB. Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas. Studies with high-definition computerised tomography. Lancet. 1984;2:187-92.
17. Klibanski A, Zervas NT. Diagnosis and management of hormone-secreting pituitary adenomas. N Engl J Med. 1991;324:822-31.
18. Landolt AM, Osterwalder V. Perivascular fibrosis in prolactinomas: is it increased by bromocriptine? J Clin Endocrinol Metab. 1984;58:1179-83.
19. Esiri MM, Bevan JS, Burke CW, Adams CB. Effect of bromocriptine treatment on the fibrous tissue content of prolactin-secreting and nonfunctioning macroadenomas of the pituitary gland. J Clin Endocrinol Metab. 1986;63:383-8.
20. Pellegrini I, Rasolonjanahary R, Gunz G, Bertrand P, Delivet S, Jedynak CP, et al. Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab. 1989;69:500-9.
21. Friedman E, Adams EF, Hoog A, Gejman PV, Carson E, Larsson C, et al. Normal structural dopamine type 2 receptor gene in prolactin-secreting and other pituitary tumors. J Clin Endocrinol Metab. 1994;78:568-74.
22. de Herder WW, Reijs AE, Kwekkeboom DJ, Hofland U, Nobels FR, Oei HY, et al. In vivo imaging of pituitary tumours using a radiolabelled dopamine D2 receptor radioligand. Clin Endocrinol (Oxf). 1996;45:755-67.
23. Pakes D. Drug therapy: bromocriptine. N Engl J Med. 1979;301:873-8.
24. Schettini G, Lombardi G, Merola B, Colao A, Miletto P, Caruso E, et al. Rapid and long-lasting suppression of prolactin secretion and shrinkage of prolactinomas after injection of long-acting repeatable form of bromocriptine (Parlodel LAR). Clin Endocrinol (Oxf). 1990;33:161-9.
25. Haase R, Jaspers C, Schulte HM, Lancranja I, Pfingsten H, Orri-Fend M, et al. Control of prolactin-secreting macroadenomas with parenteral, long-acting bromocriptine in 30 patients treated for up to 3 years. Clin Endocrinol (Oxf). 1993;38:165-76.
26. Ciccarelli E, Miola C, Grottoli S, Avataneo T, Lancranjan I, Camanni F. Long term therapy of patients with macroprolactinoma using repeatable injectable bromocriptine. J Clin Endocrinol Metab. 1993;76:484-8.
27. Katz E, Schran HF, Adashi EY. Successful treatment of a prolactin-producing pituitary macroadenoma with intravaginal bromocriptine mesylate: a novel approach to intolerance of oral therapy. Obstet Gynecol. 1989;73: 517-20.
28. Kletzky OA, Vermesh M. Effectiveness of vaginal bromocriptine in treating women with hyperprolactinemia. Fertil Steril. 1989;51:269-72.
29. Bevan JS, Davis JR. Cabergoline: an advance in dopaminergic therapy. Clin Endocrinol (Oxf). 1994;41:709-12.
30. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med. 1994;331:904-9.
31. Biller BM, Molitch ME, Vance ML, Cannistraro KB, Davis KR, Simons JA, et al. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab. 1996;81: 2338-43.
32. Colao A, Di Sarno A, Sarnacchiaro F, Ferone D, Di Renzo G, Merola B, et al. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab. 1997;82:876-83.
33. Kleinberg DL, Boyd AE 3d, Wardlaw S, Frantz AG, George A, Bryan N, et al. Pergolide for the treatment of pituitary tumors secreting prolactin or growth hormone. N Engl J Med. 1983;309:704-9.
34. Chiodini P, Liuzzi A, Cozzi R, Verde G, Oppizzi G, Dallabonzana D, et al. Size reduction of macroprolactinomas by bromocriptine or lisuride treatment. J Clin Endocrinol Metab. 1981;53:737-43.
35. Bouloux PM, Besser GM, Grossman A, Moult PJ. Clinical evaluation of lysuride in the management of hyperprolactinaemia. Br Med J (Clin Res Ed). 1987;294:1323-4.
36. Vance ML, Cragun JR, Reimnitz C, Chang RJ, Rashef E, Blackwell RE, et al. CV 205-502 treatment of hyperprolactinemia. J Clin Endocrinol Metab. 1989;68:336-9.
37. Vance ML, Lipper M, Klibanski A, Biller BM, Samaan NA, Molitch ME. Treatment of prolactin-secreting pituitary macroadenomas with the long-acting non-ergot dopamine agonist CV 205-502. Ann Intern Med. 1990; 112:668-73.
38. Homburg R, West C, Brownell J, Jacobs HS. A double-blind study comparing a new non-ergot, long-acting dopamine agonist, CV 205-502, with bromocriptine in women with hyperprolactinaemia. Clin Endocrinol (Oxf). 1990;32:565-71.
39. Brue T, Pellegrini I, Gunz G, Morange I, Dewailly D, Brownell J, et al. Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine. J Clin Endocrinol Metab. 1992;74:577-84.
40. Miller GM, Alexander JM, Bikkal HA, Katznelson L, Zervas NT, Klibanski A. Somatostatin receptor subtype gene expression in pituitary adenomas. J Clin Endocrinol Metab. 1995;80:1386-92.
41. Greenman Y, Melmed S. Heterogenous expression of two somatostatin receptor subtypes in pituitary tumors. J Clin Endocrinol Metab. 1994;78:398-403.
42. Greenman Y, Melmed S. Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage. J Clin Endocrinol Metab. 1994;79:724-9.
43. Lamberts SW, Zweens M, Klijn JG, Van Vroonhoven CC, Stefanko SZ, Del Pozo E. The sensitivity of growth hormone and prolactin secretion to the somatostatin analogue SMS 201-995 in patients with prolactinomas and acromegaly. Clin Endocrinol (Oxf). 1986;25:201-12.
44. Bronstein MD, Knoepfelmacher M, Liberman B, Marino R Jr, Germek OA, Schally AV. Absence of suppressive effect of somatostatin on prolactin levels in patients with hyperprolactinemia. Horm Metab Res. 1987;19:271-4.
45. Shimon I, Yan X, Taylor JE, Weiss MH, Culler MD, Melmed S. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J Clin Invest. 1997;100: 2386-92.
46. Nabarro JD. Acromegaly. Clin Endocrinol (Oxf). 1987;26:481-512.
47. Molitch ME. Clinical manifestations of acromegaly. Endocrinol Metab Clin North Am. 1992;21:597-614.
48. Ituarte EA, Petrini J, Hershman JM. Acromegaly and colon cancer. Ann Intern Med. 1984;101:627-8.
49. Bengtsson BA, Eden S, Ernest I, Oden A, Sjogren B. Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand. 1988;223:327-35.
50. Bates AS, Van't Hoff W, Jones JM, Clayton RN. An audit of outcome of treatment in acromegaly. Q J Med. 1993;86:293-9.
51. Melmed S, Jackson I, Kleinberg D, Klibanski A. Current treatment guidelines for acromegaly. J Clin Endocrinol Metab. 1998;83:2646-52.
52. Barkan AL, Halasz I, Dornfeld KJ, Jaffe CA, Friberg RD, Chandler WF, et al. Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly. J Clin Endocrinol Metab. 1997; 82:3187-91.
53. Fahlbusch R, Honegger J, Buchfelder M. Surgical management of acromegaly. Endocrinol Metab Clin North Am. 1992;21:669-92.
54. Melmed S, Ho K, Klibanski A, Reichlin S, Thorner M. Clinical review 75: recent advances in pathogenesis, diagnosis, and management of acromegaly. J Clin Endocrinol Metab. 1995;80:3395-402.
55. Lamberts SW, Uitterlinden P, Verschoor L, van Dongen KJ, del Pozo E. Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995. N Engl J Med. 1985;313:1576-80.
56. Shimon I, Taylor JE, Dong JZ, Bitonte RA, Kim S, Morgan B, et al. Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. J Clin Invest. 1997;99:789-98.
57. Ur E, Mather SJ, Bomanji J, Ellison D, Britton KE, Grossman AB, et al. Pituitary imaging using a labelled somatostatin analogue in acromegaly. Clin Endocrinol (Oxf). 1992;36:147-50.
58. Ezzat S, Snyder PJ, Young WF, Boyajy LD, Newman C, Klibanski A, et al. Octreotide treatment of acromegaly. A randomized, multicenter study. Ann Intern Med. 1992;117:711-8.
59. Vance ML, Harris AG. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group. Arch Intern Med. 1991;151:1573-8.
60. Newman CB, Melmed S, Snyder PJ, Young WF, Boyajy LD, Levy R, et al. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients - a clinical research center study. J Clin Endocrinol Metab. 1995;80:2768-75.
61. Lim MJ, Barkan AL, Buda AJ. Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypersecretion. Ann Intern Med. 1992;117:719-26.
62. Grunstein RR, Ho KK, Sullivan CE. Effect of octreotide, a somatostatin analog, on sleep apnea in patients with acromegaly. Ann Intern Med. 1994; 121:478-83.
63. Consensus statement: benefits versus risks of medical therapy for acromegaly. Acromegaly Therapy Consensus Development Panel. Am J Med. 1994; 97:468-73.
64. Orskov H, Christensen SE, Weeke J, Kaal A, Harris AG. Effects of antibodies against octreotide in two patients with acromegaly. Clin Endocrinol (Oxf). 1991;34:395-8.
65. Flogstad AK, Halse J, Haldorsen T, Lancranjan I, Marbach P, Bruns C, et al. Sandostatin LAR in acromegalic patients: a dose-range study. J Clin Endocrinol Metab. 1995;80:3601-7.
66. Stewart PM, Kane KF, Stewart SE, Lancranjan I, Sheppard MC. Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly. J Clin Endocrinol Metab. 1995;80:3267-72.
67. Flogstad AK, Halse J, Bakke S, Lancranjan I, Marbach P, Bruns C, et al. Sandostatin LAR in acromegalic patients: long term treatment. J Clin Endocrinol Metab. 1997;82:23-8.
68. Heron I, Thomas F, Dero M, Gancel A, Ruiz JM, Schatz B, et al. Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. J Clin Endocrinol Metab. 1993;76:721-7.
69. Giusti M, Gussoni G, Cuttica CM, Giordano G. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group. J Clin Endocrinol Metab. 1996;81:2089-97.
70. Caron P, Morange-Ramos I, Conge M, Jaquet P. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab. 1997;82:18-22.
71. Jaffe CA, Barkan AL. Treatment of acromegaly with dopamine agonists. Endocrinol Metab Clin North Am. 1992;21:713-35.
72. Colao A, Ferone D, Marzullo P, Di Sarno A, Cerbone G, Sarnacchiaro F, et al. Effect of different dopaminergic agents in the treatment of acromegaly. J Clin Endocrinol Metab. 1997;82:518-23.
73. Hewlett TA, Robertson IJA, Liddicoat A. Acromegaly: shrinkage of macroadenomas with cabergoline [Abstract]. Proceedings of The Endocrine Society 79th Annual Meeting. Minneapolis, MN, June 1997.
74. Lamberts SW, Zweens M, Verschoor L, del Pozo E. A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201-995, bromocriptine, and the combination of both drugs. J Clin Endocrinol Metab. 1986;63:16-20.
75. Flogstad AK, Halse J, Grass P, Abisch E, Djoseland O, Kutz K, et al. A comparison of octreotide, bromocriptine, or a combination of both drugs in acromegaly. J Clin Endocrinol Metab. 1994;79:461-5.
76. Chen WY, Chen N, Yun J, Wagner TE, Kopchick JJ. In vitro and in vivo studies of antagonistic effects of human growth hormone analogs. J Biol Chem. 1994;269:15892-7.
77. Chen WY, Wight DC, Metha BV, Wagner TE, Kopchick JJ. Glycine 119 of bovine growth hormone is critical for growth-promoting activity. Mol Endocrinol. 1991;5:1845-51.
78. Kovacs M, Zarandi M, Halmos G, Groot K, Serially AV. Effects of acute and chronic administration of a new potent antagonist of growth hormone-releasing hormone in rats: mechanisms of action. Endocrinology. 1996;137: 5364-9.
79. Jaffe CA, Frieberg RD, Barkan AL. Suppression of growth hormone (GH) secretion by a selective GH-releasing hormone (GHRH) antagonist. Direct evidence for involvement of endogenous GHRH in the generation of GH pulses. J Clin Invest. 1993;92:695-701.
80. Mampalam TJ, Tyrrell JB, Wilson CB. Transsphenoidal microsurgery for Cushing disease. A report of 216 cases. Ann Intern Med. 1988;109:487-93.
81. Luton JP, Mahoudeau JA, Bouchard P, Thieblot P, Hautecouverture M, Simon D, et al. Treatment of Cushing's disease by O, p'DDD. Survey of 62 cases. N Engl J Med. 1979;300:459-64.
82. Schteingart DE, McKenzie AK. Twelve-hour cycles of adrenocorticotropin and Cortisol secretion in Cushing's disease. J Clin Endocrinol Metab. 1980; 51:1195-8.
83. Miller JW, Crapo L. The medical treatment of Cushing's syndrome. Endocr Rev. 1993;14:443-58.
84. Schulte HM, Benker G, Reinwein D, Sippell WG, Allolio B. Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing's syndrome and dose-response relationship in normal subjects. J Clin Endocrinol Metab. 1990;70:1426-30.
85. Verhelst JA, Trainer PJ, Hewlett TA, Perry L, Rees LH, Grossman AB, et al. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome. Clin Endocrinol (Oxf). 1991;35:169-78.
86. Misbin RI, Canary J, Willard D. Aminoglutethimide in the treatment of Cushing's syndrome. J Clin Pharmacol. 1976;16:645-51.
87. Beck-Peccoz P, Brucker-Davis F, Persani L, Smallridge RC, Weintraub BD. Thyrotropin-secreting pituitary tumors. Endocr Rev. 1996;17:610-38.
88. Comi RJ, Gesundheit N, Murray L, Gorden P, Weintraub BD. Response of thyrotropin-secreting pituitary adenomas to a long-acting somatostatin analogue. N Engl J Med. 1987;317:12-7.
89. Chanson P, Weintraub BD, Harris AG. Octreotide therapy for thyroid-stimulating hormone-secreting pituitary adenomas. A follow-up of 52 patients. Ann Intern Med. 1993;119:236-40.
90. Gancel A, Vuillermet P, Legrand A, Catus F, Thomas F, Kuhn JM. Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas. Clin Endocrinol (Oxf). 1994; 40:421-8.
91. Ridgway EC, Klibanski A, Ladenson PW, Clemmons D, Beitins IZ, McArthur JW, et al. Pure alpha-secreting pituitary adenomas. N Engl J Med. 1981;304:1254-9.
92. Melen O. Neuro-ophthalmologic features of pituitary tumors. Endocrinol Metab Clin North Am. 1987;16:585-608.
93. Berezin M, Olchovsky D, Pines A, Tadmor R, Lunenfeld B. Reduction of follicle-stimulating hormone (FSH) secretion in FSH-producing pituitary adenoma by bromocriptine. J Clin Endocrinol Metab. 1984;59:1220-2.
94. Vance ML, Ridgway EC, Thorner MO. Follicle-stimulating hormone and α-subunit-secreting pituitary tumor treated with bromocriptine. J Clin Endocrinol Metab. 1985;61:580-4.
95. Klibanski A, Deutsch PJ, Jameson JL, Ridgway EC, Crowley WF, Hsu DW, et al. Luteinizing hormone-secreting pituitary tumor: biosynthetic characterization and clinical studies. J Clin Endocrinol Metab. 1987;64:536-42.
96. de Bruin TW, Kwekkeboom DJ, Van't Verlaat JW, Reubi JC, Krenning EP, Lamberts SW, et al. Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro. J Clin Endocrinol Metab. 1992;75:1310-7.
97. Katznelson L, Oppenheim DS, Coughlin JF, Kliman B, Schoenfeld DA, Klibanski A. Chronic somatostatin analog administration in patients with α-subunit-secreting pituitary tumors, J Clin Endocrinol Metab. 1992;75: 1318-25.
98. Plockinger U, Reichel M, Fett U, Saeger W, Quabbe HJ. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy. J Clin Endocrinol Metab. 1994;79:1416-23.
99. Snyder PJ. Gonadotroph adenomas. In: Melmed S. The Pituitary. Cambridge, MA: Blackwell Science; 1995:559-75.
100. McGrath GA, Goncalves R, Udupa JK, Grossman RI, Pavlou SN, Molitch ME, et al. New technique for quantification of pituitary adenoma size: use in evaluating treatment of gonadotroph adenomas with a gonadotropin-releasing hormone antagonist. J Clin Endocrinol Metab. 1993;76: 1363-8.